Kodiak Sciences Q1 2023 net loss $70.8M; four Phase 3 readouts expected in Q3 2023

Kodiak Sciences Inc.

2023-Q1 EPS reported -$1.35

Cash position $421.2M; net loss $70.8M ($1.35/share) vs $95.7M ($1.83/share) Q1 2022.
R&D expenses $56.5M (down from $76.2M) due to maturation of tarcocimab program and manufacturing timing.
Topline data for GLEAM, GLIMMER, DAYLIGHT studies expected July 2023; GLOW study expected September 2023.
BEACON Phase 3 study met primary endpoint in 2022; company plans single BLA for tarcocimab if successful.
Phase 1 dosing started for KSI-501 bispecific antibody biopolymer conjugate in DME.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kodiak Sciences Inc. reported the quarter ended March 31, 2023 results: net income $70.8 million, EPS $1.35 per share.

Period: the quarter ended March 31, 2023
Net income: $70.8 million
EPS: $1.35 per share
Result: reported results

Exact text from the filing

The net loss for the first quarter of 2023 was $70.8 million, or $1.35 per share on both a basic and diluted basis

View on SEC.gov

Browse all earnings releases →

Kodiak Sciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-022193

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.